López-Hernández Luz B, van Heusden Dave, Soriano-Ursúa Marvin A, Figuera-Villanueva Luis, Vázquez-Cárdenas Norma A, Canto Patricia, Gómez-Díaz Benjamín, Coral-Vázquez Ramón M
Centro Universitario de Cienciasde la Salud, Universidad de Guadalajara, México.
Rev Neurol. 2011 Jun 16;52(12):720-4.
Duchenne muscular dystrophy (DMD) is a genomic disorder characterized by progressive muscle wasting and weakness due to the absence or abnormal function of dystrophin; a protein that protects muscle cells from mechanical induced stress during contraction. Mutations in the DMD gene, may lead to different clinical phenotypes, collectively known as dystrophinopathies, of which DMD has the earliest onset and most severe progression.
We report a novel deletion of exons 24-41, predicted to maintain the reading frame and expected to result in a mild phenotype. Conversely, the patient has a severe DMD phenotype.
Our report supports the hypothesis that disruption of the gamma-actin-binding site located in the central rod domain plays a crucial role in the shock absorber function of dystrophin in muscle cells. Description of pathogenic variants in the DMD gene and the resulting phenotypes has important implications on the designing of molecular therapeutic approaches for DMD.
杜氏肌营养不良症(DMD)是一种基因组疾病,其特征是由于肌营养不良蛋白缺乏或功能异常导致进行性肌肉萎缩和无力;肌营养不良蛋白是一种在收缩过程中保护肌肉细胞免受机械诱导应激的蛋白质。DMD基因的突变可能导致不同的临床表型,统称为肌营养不良蛋白病,其中DMD发病最早且进展最严重。
我们报告了一个外显子24 - 41的新型缺失,预计可维持阅读框并导致轻度表型。相反,该患者具有严重的DMD表型。
我们的报告支持以下假设,即位于中央杆状结构域的γ-肌动蛋白结合位点的破坏在肌营养不良蛋白在肌肉细胞中的减震器功能中起关键作用。DMD基因中致病变体及其所产生表型的描述对DMD分子治疗方法的设计具有重要意义。